HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Immunology · Type 1 Diabetes Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Immunology · Type 1 Diabetes Therapeutic Area Assessment

147 signals · 15 insights · 589 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 74%

Evidence

751 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Immunology · Type 1 Diabetes integrates 147 signals, 15 executive insights, and 589 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 17, 2026

    FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

    The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE.

    View detail
  2. signalJul 23, 2026

    FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

    The FDA has approved a supplemental application for QTERN, a combination of dapagliflozin and saxagliptin.

    View detail
  3. signalJul 23, 2026

    FDA Approves ANDA for Tofacitinib Citrate by Sun Pharma

    The FDA has granted approval for ANDA218407, a generic version of Tofacitinib Citrate submitted by Sun Pharma.

    View detail
  4. signalJul 22, 2026

    FDA Grants Approval for Tofacitinib Citrate (ANDA217298)

    The FDA has granted approval for Tofacitinib Citrate under ANDA217298, submitted by MSN.

    View detail
  5. regulatoryJul 24, 2026

    FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    Application ANDA075351. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    View detail
  6. regulatoryJul 24, 2026

    FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)

    Application ANDA040419. Sponsor: SPECGX LLC. Submission status: AP. Submission type: SUPPL. Active ingredients: ACETAMINOPHEN, CODEINE PHOSPHATE.

    View detail
  7. regulatoryJul 24, 2026

    FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    Application ANDA075231. Sponsor: LGM PHARMA. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    View detail
  8. regulatoryJul 24, 2026

    FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    Application ANDA074951. Sponsor: STEVENS J. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    View detail
  9. insightJul 21, 2026

    Lilly's Revenue Surge Signals Competitive Shift in GLP-1 Market

    Lilly's impressive revenue growth and raised guidance signal robust demand for its diabetes treatments, positioning the company favorably in the competitive GLP-1 landscape. This momentum may compel competitors to reevaluate their market strategies and product offerings. Regulatory context from MHRA (Guidance: Submit changes to labels and Patient Information Leaflets as a self-certification) supports the near-term read. Assessment grounded in 20 ranked evidence items (20 high-relevance).

    View detail
  10. insightJul 3, 2026

    Emerging Competitive Threat in Continuous Glucose Monitoring Market from SAVA Technologies

    The initiation of SAVA Technologies' pilot trial for its Continuous Glucose Monitor is significant as it could disrupt the competitive landscape in diabetes management. Success in this trial may lead to market entry, challenging established players and altering market dynamics. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 15 ranked evidence items (8 high-relevance).

    View detail
  11. insightJul 3, 2026

    Insulet's Omnipod Recall: Strategic Risks and Competitive Dynamics in Insulin Delivery

    The recall of Insulet's Omnipod Pods due to insulin leakage poses significant risks to the company's market share and patient trust. This situation necessitates a thorough assessment of potential impacts on sales forecasts and reputational strategies. Regulatory context from FDA (Insulin Pump Recall: Insulet Removes Omnipod Pods) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

    View detail
  12. insightJul 1, 2026

    Competitive Dynamics in Hereditary Angioedema Trials: Astria vs.

    The initiation of Phase 3 trial for navenibart by Astria Therapeutics is significant as it positions the company to potentially disrupt the hereditary angioedema (HAE) treatment landscape. Success in this trial could enhance Astria's competitive standing and market share, impacting existing players in the HAE market. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 13 ranked evidence items (3 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 15 risk-calibrated assessments for portfolio review. 589 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 8 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    77%

    Application ANDA075351. Sponsor: NOVITIUM PHARMA. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    Source: FDA

    View evidence

  • FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)

    77%

    Application ANDA040419. Sponsor: SPECGX LLC. Submission status: AP. Submission type: SUPPL. Active ingredients: ACETAMINOPHEN, CODEINE PHOSPHATE.

    Source: FDA

    View evidence

  • FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    77%

    Application ANDA075231. Sponsor: LGM PHARMA. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    Source: FDA

    View evidence

  • FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)

    77%

    Application ANDA074951. Sponsor: STEVENS J. Submission status: AP. Submission type: SUPPL. Active ingredients: ASPIRIN, BUTALBITAL, CAFFEINE, CODEINE PHOSPHATE.

    Source: FDA

    View evidence

  • FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)

    77%

    Application ANDA087006. Sponsor: PHARMOBEDIENT. Submission status: AP. Submission type: SUPPL. Active ingredients: ACETAMINOPHEN, CODEINE PHOSPHATE.

    Source: FDA

    View evidence

  • Rare Disease Drug Approvals

    66%

    This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

    Source: FDA

    View evidence

  • Lilly's Revenue Surge Signals Competitive Shift in GLP-1 Market

    92%

    Lilly's impressive revenue growth and raised guidance signal robust demand for its diabetes treatments, positioning the company favorably in the competitive GLP-1 landscape. This momentum may compel competitors to reevaluate their market strategies and product offerings. Regulatory context from MHRA (Guidance: Submit changes to labels and Patient Information Leaflets as a self-certification) supports the near-term read. Assessment grounded in 20 ranked evidence items (20 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Competitive Threat in Continuous Glucose Monitoring Market from SAVA Technologies

    69%

    The initiation of SAVA Technologies' pilot trial for its Continuous Glucose Monitor is significant as it could disrupt the competitive landscape in diabetes management. Success in this trial may lead to market entry, challenging established players and altering market dynamics. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 15 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Insulet's Omnipod Recall: Strategic Risks and Competitive Dynamics in Insulin Delivery

    53%

    The recall of Insulet's Omnipod Pods due to insulin leakage poses significant risks to the company's market share and patient trust. This situation necessitates a thorough assessment of potential impacts on sales forecasts and reputational strategies. Regulatory context from FDA (Insulin Pump Recall: Insulet Removes Omnipod Pods) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Competitive Dynamics in Hereditary Angioedema Trials: Astria vs.

    56%

    The initiation of Phase 3 trial for navenibart by Astria Therapeutics is significant as it positions the company to potentially disrupt the hereditary angioedema (HAE) treatment landscape. Success in this trial could enhance Astria's competitive standing and market share, impacting existing players in the HAE market. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 13 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Enhancing Vaccine Efficacy in the Elderly Through Immunostimulatory Adjuvants

    64%

    The discovery of an immunostimulatory adjuvant that enhances vaccine responses in aged models is significant for addressing immunosenescence in the elderly. This could lead to improved vaccine efficacy in a demographic that is often underserved, presenting both a clinical opportunity and a competitive advantage for pharma companies focused on vaccine development. Regulatory context from FDA (FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Inventia's Dapagliflozin Supplement Application Acceptance Signals Market Shift

    67%

    The FDA's acceptance of the supplemental application for dapagliflozin by Inventia is a significant regulatory milestone that could reshape competitive dynamics in the diabetes market. Pharma strategy teams should evaluate the implications for their portfolios and prepare for potential shifts in market share and competitive positioning. Regulatory context from FDA (FDA AP — DAPAGLIFLOZIN (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (10 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment

    Regulatory Approval

  • FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

    Regulatory Approval

  • FDA Approves ANDA for Tofacitinib Citrate by Sun Pharma

    Regulatory Approval

  • FDA Grants Approval for Tofacitinib Citrate (ANDA217298)

    Regulatory Approval

  • FDA Grants Approval for Tofacitinib Citrate ANDA220137

    Regulatory Approval

  • FDA Approves Supplement for ULTOMIRIS (Ravulizumab-Cwvz)

    Regulatory Approval

  • Lilly Q1 2026 Revenue Up 56%, Raises Full Year Guidance

    Pipeline Update

  • FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma

    Regulatory Approval

Insights

  • Lilly's Revenue Surge Signals Competitive Shift in GLP-1 Market

    Diabetes · GLP-1

  • Emerging Competitive Threat in Continuous Glucose Monitoring Market from SAVA Technologies

    Diabetes · Continuous Glucose Monitoring

  • Insulet's Omnipod Recall: Strategic Risks and Competitive Dynamics in Insulin Delivery

    Diabetes · Insulin Delivery

  • Competitive Dynamics in Hereditary Angioedema Trials: Astria vs.

    Immunology · Hereditary Angioedema

  • Enhancing Vaccine Efficacy in the Elderly Through Immunostimulatory Adjuvants

    Immunology · Vaccine Development

  • Inventia's Dapagliflozin Supplement Application Acceptance Signals Market Shift

    Diabetes · SGLT2 Inhibitor

  • Optimizing mAb Formulations Through Excipient Interactions for Competitive Advantage

    Immunology · Monoclonal Antibodies

  • Emerging Generic Competition for Tofacitinib: Strategic Implications for Market Players

    Immunology · JAK Inhibitor

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Merck

    132 signals

  • AstraZeneca

    127 signals

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Janssen

    36 signals

  • AbbVie

    26 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.